Erectile dysfunction · Comparison study · 2026
Does shockwave work better for younger men with erection problems?
In this study of 52 men who all had the same six shockwave sessions, erection scores rose in both age groups. Men under 50 ended higher than men 50 and over: about 22 against 18 at six months.
Improved in both age groups- men with mild to moderate erection problems
- 52
- sessions over 3 weeks
- 6
- months of follow-up
- 6
Good to know: The age groups differed in smoking, weight and other health conditions.
Albayrak İH, Demir M, Danacıoğlu YO, et al. Sexual Medicine, 2026 · Read the paper ↗
How this study worked
The treatment
Under 50
Focused, twice a week for 3 weeks
- Sessions
- 6, two a week
- Pulses
- 1,500 per session · 300 at each of five points
- Strength
- 0.15mJ/mm² · 3 per second
- Numbing
- Not mentioned
- Device
- Modus Focus
50 and over
Focused, twice a week for 3 weeks
- Sessions
- 6, two a week
- Pulses
- 1,500 per session · 300 at each of five points
- Strength
- 0.15mJ/mm² · 3 per second
- Numbing
- Not mentioned
- Device
- Modus Focus
Compared with: Men under 50 vs men 50 and over, all given the same treatment
Settings are what each study used, not a prescription.
Who took part
52 men aged 26–80 with mild to moderate erection problems and no earlier treatment: 27 under 50 and 25 aged 50 or over.
Side effects
The study does not report side effects.
All the numbers and the full appraisal
What the full paper reports.
Fifty-two patients with mild-to-moderate erectile dysfunction; age-stratified <50 years (n=27) and ≥50 years (n=25), without prior ED treatment. Ages 26–80; mean 49.6±13.6.
Age-defined observational cohort; not randomized.
Age-defined observational cohort; not randomized.
IIEF-5 score at 1 month3 reported outcomes
IIEF-5 score at 1 month
International Index of Erectile Function-5 (IIEF-5) Score points
Age <50 versus age ≥50; younger group higher
Between age-cohort comparison (Mann–Whitney U in Table 2; adjusted ANCOVA in Results)
Table 2 raw means: 21.9 vs 17.6; adjusted means controlling for smoking, BMI and comorbidities: 21.86 vs 17.91. Both analyses report higher scores in the younger cohort at this follow-up. Raw Table 2 between-age-group p=.000; adjusted ANCOVA between-age-group p=<.001. These correspond to distinct raw and adjusted analyses, respectively.
Analysis details and source
These are age-cohort differences after a shared treatment, not randomized treatment effects. The Results narrative contains inconsistent older-group values, flagged in limitations. The Results also report adjusted baseline means 13.18 vs 13.04 (p=.869); the mixed model gives baseline p=.474. Keep those baseline tests separate from follow-up comparisons.
IIEF-5 score at 3 months
International Index of Erectile Function-5 (IIEF-5) Score points
Age <50 versus age ≥50; younger group higher
Between age-cohort comparison (Mann–Whitney U in Table 2; adjusted ANCOVA in Results)
Table 2 raw means: 22.1 vs 19.0; adjusted means controlling for smoking, BMI and comorbidities: 22.02 vs 18.90. Both analyses report higher scores in the younger cohort at this follow-up. Raw Table 2 between-age-group p=.001; adjusted ANCOVA between-age-group p=.003. These correspond to distinct raw and adjusted analyses, respectively.
Analysis details and source
These are age-cohort differences after a shared treatment, not randomized treatment effects. The Results narrative contains inconsistent older-group values, flagged in limitations. The Results also report adjusted baseline means 13.18 vs 13.04 (p=.869); the mixed model gives baseline p=.474. Keep those baseline tests separate from follow-up comparisons.
IIEF-5 score at 6 months
International Index of Erectile Function-5 (IIEF-5) Score points
Age <50 versus age ≥50; younger group higher
Between age-cohort comparison (Mann–Whitney U in Table 2; adjusted ANCOVA in Results)
Table 2 raw means: 21.9 vs 18.2; adjusted means controlling for smoking, BMI and comorbidities: 21.30 vs 17.82. Both analyses report higher scores in the younger cohort at this follow-up. Raw Table 2 between-age-group p=.000; adjusted ANCOVA between-age-group p=.002. These correspond to distinct raw and adjusted analyses, respectively.
Analysis details and source
These are age-cohort differences after a shared treatment, not randomized treatment effects. The Results narrative contains inconsistent older-group values, flagged in limitations. The Results also report adjusted baseline means 13.18 vs 13.04 (p=.869); the mixed model gives baseline p=.474. Keep those baseline tests separate from follow-up comparisons.
Erection Hardness Score at 1 month3 reported outcomes
Erection Hardness Score at 1 month
Erection Hardness Score (EHS) Score points; observed baseline values 0–3 (Table 1)
Age <50 versus age ≥50
Between age-cohort comparison (Mann–Whitney U)
Table 2 reports means±SD 2.7±0.6 vs 2.6±0.6; no significant between-group difference. Between-age-group p=.509. The Results separately state that EHS increased significantly within each age group after ESWT; this does not establish a between-group treatment effect.
Analysis details and source
No equivalence inference; within-group changes are distinct from age-cohort comparisons. The paper does not state the EHS scale range; 0–3 is the observed baseline range (Table 1, Min–max column).
Erection Hardness Score at 3 months
Erection Hardness Score (EHS) Score points; observed baseline values 0–3 (Table 1)
Age <50 versus age ≥50
Between age-cohort comparison (Mann–Whitney U)
Table 2 reports means±SD 2.9±0.6 vs 2.7±0.6; no significant between-group difference. Between-age-group p=.395. The Results separately state that EHS increased significantly within each age group after ESWT; this does not establish a between-group treatment effect.
Analysis details and source
No equivalence inference; within-group changes are distinct from age-cohort comparisons. The paper does not state the EHS scale range; 0–3 is the observed baseline range (Table 1, Min–max column).
Erection Hardness Score at 6 months
Erection Hardness Score (EHS) Score points; observed baseline values 0–3 (Table 1)
Age <50 versus age ≥50
Between age-cohort comparison (Mann–Whitney U)
Table 2 reports means±SD 2.7±0.5 vs 2.5±0.7; no significant between-group difference. Between-age-group p=.404. The Results separately state that EHS increased significantly within each age group after ESWT; this does not establish a between-group treatment effect.
Analysis details and source
No equivalence inference; within-group changes are distinct from age-cohort comparisons. The paper does not state the EHS scale range; 0–3 is the observed baseline range (Table 1, Min–max column).
How treatment was delivered
Modus Focus (electrohydraulic; Inceler Medical); twice weekly for 3 weeks, six sessions. 1,500 shocks/session (300 at each of five points on both lateral corpora cavernosa), 0.15 mJ/mm², 3 Hz. Same protocol for all; PDE5 inhibitors withheld during treatment and follow-up.
The study does not report a systematic adverse-event outcome or count in the inspected article.
Prospective controlled age-cohort study, not randomized and without placebo/non-ESWT comparator; age is entangled with comorbidities, BMI and smoking differences.
Small sample (n=52) and limited follow-up to 6 months; the study cannot determine whether ESWT itself caused improvement.
The Results narrative gives ≥50-year IIEF-5 values as 13.3, 17.6 and 19 at months 1, 3 and 6; Table 2 instead reports 17.6, 19.0 and 18.2. Table 2 and adjusted ANCOVA values are recorded above; the conflict is not reconciled.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Prospective controlled age-cohort study, not randomized and without placebo/non-ESWT comparator; age is entangled with comorbidities, BMI and smoking differences.
- Small sample (n=52) and limited follow-up to 6 months; the study cannot determine whether ESWT itself caused improvement.
- The Results narrative gives ≥50-year IIEF-5 values as 13.3, 17.6 and 19 at months 1, 3 and 6; Table 2 instead reports 17.6, 19.0 and 18.2. Table 2 and adjusted ANCOVA values are recorded above; the conflict is not reconciled.
Source-linked critical reading
Nonrandomized age-group comparison within a treated cohort
Technical source record
Full text, both raw tables, figure caption, protocol, raw and adjusted results, limitations and declarations reviewed.
Younger patients had higher follow-up IIEF-5 scores, but this study cannot separate the effect of shockwave from placebo or other age-related differences.
Does age modify IIEF-5 and erection-hardness outcomes after LI-ESWT for mild-to-moderate erectile dysfunction?
Prospective controlled age-cohort study; all patients received identical LI-ESWT; no placebo or untreated control.
52 treatment-naive patients with mild-to-moderate ED (IIEF 11–25): 27 aged <50 and 25 aged ≥50.
Focused electrohydraulic LI-ESWT, Modus Focus; six sessions, twice weekly for 3 weeks; 1,500 shocks/session, 0.15 mJ/mm², 3 Hz. PDE5 inhibitors withheld.
Age strata compared after the same treatment; no treatment control.
IIEF-5 scores were higher in the younger cohort at months 1, 3, 6 by raw and adjusted analyses. EHS means also rose in both cohorts, with no significant age-group contrast at any follow-up. Raw Table 2 p-values for younger-vs-older IIEF-5 were .000/.001/.000 at months 1/3/6; adjusted ANCOVA p-values were <.001/.003/.002. The adjusted baseline comparison was p=.869 and mixed-model baseline p=.474. EHS between-age-group p-values were .509/.395/.404; the Results separately report significant within-group EHS increases after ESWT.
In the linear mixed model, the age-by-time interaction was significant (all follow-up time points p<.001). These are comparisons between age groups, not a controlled estimate of ESWT efficacy. Age-cohort comparisons remain distinct from treatment efficacy because every participant received ESWT and there was no untreated or placebo group. The exact raw/adjusted IIEF tests and EHS null tests are listed by follow-up in structured outcomes.
No systematic adverse-event reporting was found in the article.
Small nonrandomized sample, no placebo group, differing comorbidity/smoking/BMI profiles and inconsistent older-group IIEF values between prose and Table 2.
Suggests age may be associated with response among treated patients but cannot establish treatment efficacy or causation.
Large randomized sham-controlled trials should stratify age, control comorbidity and report consistent scores, clinically important response and adverse events.
Read the original article.
Is extracorporeal shock wave therapy more effective in younger patients in the treatment of mild-to-moderate erectile dysfunction? A prospective controlled study.
Albayrak İH, Demir M, Danacıoğlu YO, Toprak T, Kavukçu A, Pelit ES. · Sexual medicine · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →